Novel p2y12 receptor antagonists
AssigneeRheinische Friedrich-Wilhelms-Universität Bonn
InventorsChrista E. Müller, Younis Baqi
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel P2Y12 receptor antagonists useful for treating, alleviating and/or preventing diseases and disorders related to P2Y12 receptor function as well as pharmaceutical compositions comprising such compounds and methods for preparing such compounds. The present invention is further directed to the use of these compounds, alone or in combination with other therapeutic agents, for the alleviation, prevention and/or treatment of diseases and disorders, especially the use as antithrombotic agents for inhibiting platelet aggregation.
Claims25
A compound of Formula I:
- wherein:
- A and B are independently selected from the group consisting of CH2, O, S, NH, C═O, C═NH, C═S, or C═N—OH;
- X is selected from the group consisting of NH, O, S, C═O, and CH2;
- R1 and R2 are independently selected from the group consisting of hydrogen, unsubstituted or substituted C1-C10 alkyl, unsubstituted or substituted C1-C10 alkenyl, unsubstituted or substituted C1-C10 alkynyl, unsubstituted or substituted C3-C8 cycloalkyl, unsubstituted or substituted C1-C10 alkoxy, unsubstituted or substituted C3-C8 cycloalkoxy, unsubstituted or substituted C6-C14 aryl, an unsubstituted or substituted 5- to 10-membered heteroaryl wherein 1 to 4 ring atoms are independently selected from nitrogen, oxygen or sulfur, an unsubstituted or substituted 5- to 10-membered heteroalicyclic ring wherein 1 to 3 ring atoms are independently nitrogen, oxygen or sulfur, —OR, —C(O)R, —C(O)OR, —C(O)NRR′, —NRR′, —S(O)2R, —S(O)2OR, and —S(O)2NRR′;
- R3 is selected from the group consisting of hydrogen, unsubstituted or substituted C1-C10 alkyl, unsubstituted or substituted C1-C10 alkenyl, unsubstituted or substituted C1-C10 alkynyl, unsubstituted or substituted C3-C8 cycloalkyl, unsubstituted or substituted C1-C10 alkoxy, unsubstituted or substituted C3-C8 cycloalkoxy, unsubstituted or substituted C6-C14 aryl, an unsubstituted or substituted 5- to 10-membered heteroaryl wherein 1 to 4 ring atoms are independently selected from nitrogen, oxygen or sulfur, an unsubstituted or substituted 5- to 10-membered heteroalicyclic ring wherein 1 to 3 ring atoms are independently nitrogen, oxygen or sulfur, alkylaryl, alkylheteroaryl, an unsubstituted or substituted 7 to 12-membered bicyclic alkyl or heterocyclic ring wherein 1 to 3 ring members are independently nitrogen, oxygen or sulfur, an unsubstituted or substituted 10 to 16-membered tricyclic alkyl or heterocyclic ring wherein 1 to 3 ring members are independently nitrogen, oxygen or sulfur,
- R4 and R5 are hydrogen, or, combined, R4 and R5 may form, together with the carbon atoms to which they are attached, a group selected from the group consisting of unsubstituted or substituted C3-C8 cycloalkyl, unsubstituted or substituted C6-C14 aryl, unsubstituted or substituted 5- to 10-membered heteroaryl wherein 1 to 4 ring atoms are independently selected from nitrogen, oxygen or sulfur, or unsubstituted or substituted 5- to 10-membered heteroalicyclic ring wherein 1 to 3 ring atoms are independently nitrogen, oxygen or sulfur;
- R6 represents one to four substituents independently selected from the group consisting of hydrogen, halogen, unsubstituted or substituted C1-C4 alkyl, alkenyl or alkynyl, an unsubstituted or substituted 5- to 10-membered heteroaryl wherein 1 to 4 ring atoms are independently selected from nitrogen, oxygen or sulfur, an unsubstituted or substituted 5- to 10-membered heteroalicyclic ring wherein 1 to 3 ring atoms are independently nitrogen, oxygen or sulfur, —OR, —NRR′, —NO2, unsubstituted or substituted C1-C4 alkoxy, —C(O)R, —C(O)OR, —C(O)NRR′, —S(O)2R, —S(O)2OR, and —S(O)2NRR′;
- Y is selected from the group consisting of hydrogen, halogen, NH, O, S, CH2, CH2CH2, C(O), C(O)O, S(O)2O, or unsubstituted C1-C4 alkoxy, wherein when Y is hydrogen, halogen or alkoxy R7 is missing;
- R7 is selected from the group consisting of hydrogen, halogen, —OR, unsubstituted or substituted C1-C10 alkyl, alkenyl or alkynyl, unsubstituted or substituted C1-C10 alkoxy, unsubstituted or substituted C3-C8 cycloalkoxy, unsubstituted or substituted C3-C8 cycloalkyl, unsubstituted or substituted C6-C14 aryl, an unsubstituted or substituted 5- to 10-membered heteroaryl wherein 1 to 4 ring atoms are independently selected from nitrogen, oxygen or sulfur, an unsubstituted or substituted 5- to 10-membered heteroalicyclic wherein 1 to 3 ring atoms are independently nitrogen, oxygen or sulfur, —C(O)R, —C(O)OR, —C(O)NRR′, —NRR′, —S(O)2R, —S(O)2OR, —S(O)2NRR′, and —P(O)RR′;
- and
- R and R′ are independently selected from the group consisting of hydrogen and unsubstituted C1-C4 alkyl;
- or a pharmaceutically acceptable salt or prodrug thereof.
19-22. (canceled)
The method of claim 20, wherein the disease or disorder is selected from the group of stroke, myocardial infarction, myocardial ischemia, vascular diseases, coronary artery disease, peripheral artery disease, atherosclerosis, cerebrovascular disease, embolisms and CNS disorders.
Dependencies are inferred from the claim text.